SPRY Dividend: ARS Pharmaceuticals Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

SPRY Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	142	89	0	1	0	0
Revenue Growth (YoY)	7,000%	--	-100%	--	--	--
Cost of Revenue	15	0	--	--	--	--
Gross Profit	127	88	--	--	--	--
Selling, General & Admin	205	71	47	18	28	8
Research & Development	12	19	20	18	61	24
Operating Expenses	218	91	67	36	89	32
Other Non Operating Income (Expenses)	11	11	13	1	--	--
Pretax Income	-79	8	-54	-34	-89	-32
Income Tax Expense	--	0	--	--	--	--
Net Income	-80	7	-54	-34	-89	-32
Net Income Growth	63%	-112.99%	59%	-62%	178%	39%
Shares Outstanding (Diluted)	98.8	102.39	95.21	39.96	34.93	34.7
Shares Change (YoY)	2%	8%	138%	14%	1%	5%
EPS (Diluted)	-0.81	0.07	-0.57	-0.87	-2.56	-0.95
EPS Growth	60%	-113.99%	-34%	-66%	169%	32%
Free Cash Flow	-86	12	-59	-40	-68	-32
Free Cash Flow Per Share	-0.87	0.11	-0.61	-1	-1.94	-0.92
Gross Margin	89.43%	98.87%	--	--	--	--
Operating Margin	-63.38%	-3.37%	0%	-3,500%	0%	0%
Profit Margin	-56.33%	7.86%	0%	-3,400%	0%	0%
Free Cash Flow Margin	-60.56%	13.48%	0%	-4,000%	0%	0%
EBITDA	-90	-3	-67	-35	-89	-32
EBITDA Margin	-63.38%	-3.37%	0%	-3,500%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-90	-3	-67	-35	-89	-32
EBIT Margin	-63.38%	-3.37%	0%	-3,500%	0%	0%
Effective Tax Rate	--	0%	--	--	--	--